- Global air purifier market expected to grow to $90 billion with analysts projecting CAGR between 10 and 42%
- New RxAir400 Pro UV-C bulb replacement cartridge provides 18,000 vs 9,000 hr. use.
- Wall mount offers more placement options to safely inactivate >99.9% of pathogens reducing occupant virus exposure risk in facilities such as schools, restaurants, retail and offices
Worcester, MA, July 22, 2020 (GLOBE NEWSWIRE) -- With heightened concern about protection from harmful airborne viruses, Vystar Corporation’s (OTCQB: VYST) RxAir®400 Germicidal Ultraviolet (UV-C) light air purification systems offers new features and options that will make it easier to treat airborne pathogens wherever you go indoors. RxAir400 is a smaller, consumer/small business-sized version of the industrial size Rx3000 FDA-certified Class II medical device UV light air purifier designed for disinfection use in hospitals. RxAir400 will now feature an ergonomic integrated handle for easier room-to-room portability, plus offer two new accessory options:
- Extended Life 18,000 Hour RxAir400 UV-C Pro bulb replacement cartridge - UV bulbs have limited life for germicidal effectiveness. RxAir units and bulb cartridges have interactive chips that communicate to alert users as the bulb approaches the end of life and needs to be replaced. RxAir 400 comes with its standard 9000 hr. UVC bulb cartridge good for approximately one year of regular use before requiring replacement. The new UVC Pro replacement cartridge has a lifespan of 18,000 hours, or approximately two years of normal use. Cartridges include free return and disposal of spent cartridges.
- Wall mount bracket – New low profile wall mount bracket makes it easier to put RxAir in an optimal location when traffic patterns and furniture layout are not conducive to floor placement. The low profile bracket allows you to easily lift unit off the bracket to transport room to room to safely inactivate >99.9% of pathogens, reducing virus exposure risk in occupied facilities such as schools, restaurants, retail and offices.
Vystar is currently taking pre-orders on its RxAir.com website for new units, replacement bulb cartridges and wall mount brackets expected to be in stock in mid- to late August – just in time as students head back to school.
“A main advantage of RxAir is that it can operate safely in occupied spaces to continuously process the air up to eight times per hour, inactivating or killing the pathogens expelled as people talk, breathe, cough, sneeze or sing to help reduce risk of exposure for those in the room,” stated Bryan Stone, MD, Internal Medicine and Nephrology, and Chief of Medicine for Desert Regional Medical Center. “When near people who aren’t wearing masks and may be asymptomatic, it is reassuring to have RxAir treating pathogens they may be expelling.”
“Given the growing body of evidence that Coronavirus SARS CoV-2 may be transmitted through airborne means or aerosolization noted by the CDC1,2, and hundreds of scientists worldwide3,4,5, it is wise to address all modes of possible transmission,” Dr. Stone noted. “We strongly encourage people to wear face masks and follow other CDC recommended surface and personal disinfection practices, along with using RxAir to decrease their pathogen exposure risk as much as possible.”
“RxAir400’s ViraTech technology is one of the few UV light air purification technologies proven in EPA- and FDA-certified laboratory testing to inactivate more than 99.9% of airborne viruses (including multiple coronavirus strains), bacteria and other pathogens that cause pneumonia, influenza, MRSA (staph), streptococcus (strep throat), whooping cough, tuberculosis (TB), common cold, measles and a myriad of other antibiotic-resistant and viral infections,” Dr. Stone explained. “Hospitals and healthcare facilities have been using ultraviolet germicidal irradiation (UVGI) with UV-C light for airborne infection control for decades because it is so effective. It also reduces concentration of volatile organic compounds and odors as well as air pollution linked to sleep disorders.” (See RxAir video: https://www.youtube.com/watch?v=uBTwQKvK7Zg)
Wladyslaw Kowalski, PhD, PE, is one of the world’s foremost experts on air cleaning design and construction, indoor air quality issues, including mold and bacterial contamination and hospital infection control. Dr. Kowalski authored numerous research papers and did testing analysis for the ViraTech technology used in the RxAir product line. His research and analysis of test results are available upon request.6, 7, 8. Additionally, Dr. Kowalski, independent of RxAir, along with Thomas J. Walsh and Vidmantas Petraitis, both of the Weill Cornell Medical College of Cornell University, have published a technical report titled “2020 COVID-19 Coronavirus Ultraviolet Susceptibility” which further details the impact of UV light on COVID-19.9
Air Purifier Demand Projected to Skyrocket
Grandview Research’s report in July 2020 stated, “The enforcement of lockdown across the countries globally has led to the increased demand for air purifiers in the past couple of months. Moreover, as air purifiers are effective against various viruses, the demand in several countries is expected to witness significant growth owing to the outbreak of COVID-19. Few manufacturers are claiming that their air purifiers are an ideal option for neutralizing as well as effectively controlling the spread of coronavirus. In addition, consumers are buying air purifiers across the globe as a precautionary measure to mitigate indoor air pollution and to clean indoor air to avoid the novel coronavirus infection.”
Grandview estimated that the global air purifier market size was USD $8.04 billion in 2019 and is expected to register a Compound Annual Growth Rate (CAGR) of 10.8% through 2027.
Market Research firm Arizton Advisory & Intelligence is even more optimistic -- projecting that the global portable air purifier market will grow at a CAGR of around 42% between 2019-2025 to reach $90 billion by 2025 due to “exponential rise in demand for clean air, owing to the rising population levels coupled with growing respiratory issue and epidemic spread across the globe”
For information on how to become an RxAir/Rx3000 distributor and/or bulk pricing, contact
Lee Howley, lhowley@vytex.com
Follow Vystar, Rx3000, RxAir and Vytex® news on social media:
Twitter: @VystarCompany
#Coronavirus
#Covid
#UVLight
#UVdisinfection
#UVCdisinfection
# # #
Sources:
1 Centers for Disease Control (2020, April 29) Decontamination & Reuse of Filtering Facepiece Respirators. https://www.cdc.gov/coronavirus/2019-ncov/hcp/ppe-strategy/decontamination-reuse-respirators.html. (Accessed July 21, 2020)
2 Guo Z, Wang Z, Zhang S, et al. Aerosol and Surface Distribution of Severe Acute Respiratory Syndrome Coronavirus 2 in Hospital Wards, Wuhan, China, 2020. Emerging Infectious Diseases. 2020;26(7):1583-1591. doi:10.3201/eid2607.200885. https://wwwnc.cdc.gov/eid/article/26/7/20-0885_article (accessed July 14, 2020)
3 Coffey, Donavyn, Does UV light kill the new coronavirus?, (July 12, 2020)Live Science, https://www.livescience.com/uv-light-kill-coronavirus.html, (Accessed July 14, 2020)
4 Morawska, L. & Milton, D. It is Time to Address Airborne Transmission of COVID-19, Clinical Infectious Diseases, https://doi.org/10.1093/cid/ciaa939 (2020) (accessed July 14, 2020)
5 Lewis, Dyani, Mounting evidence suggests coronavirus is airborne — but health advice has not caught up, Nature, https://www.nature.com/articles/d41586-020-02058-1 (accessed July 14, 2020)
6Kowalski, (2013, June) Residential Application of the RxAir UV light Portable Air Purification Unit
7 Kowalski, (2009, Dec. 1) Prediction of Virus Inactivation by the UV 400
8 Kowalski, (2012, Jan20) Supplemental Air Purification for Hospitals and Health Care Facilities
9 Kowalski, Walsh, Petraitis (2020, March) 2020 COVID-19 Coronavirus Ultraviolet Susceptibility
# # #
About Vystar Corporation:
Based in Worcester, Mass., Vystar® Corp. (OTCQB: VYST) is the majority owner of Rotmans Furniture and Carpet and environmentally friendly technologies and products to improve lives, such as RxAir® UV light air purification products, Vytex™ Natural Rubber Latex (NRL) and Fluid Energy Solutions. Vystar is the exclusive creator of Vytex, a multi-patented, all-natural, raw material that contains significantly reduced levels of the proteins found in natural rubber latex and can be used in over 40,000 products. Vytex NRL is a 100% renewable resource, environmentally safe, "green" and fully biodegradable. Vystar is working with manufacturers across a broad range of consumer and medical products bringing Vytex NRL to market in adhesives, gloves, balloons, condoms, other medical devices and natural rubber latex foam mattresses, toppers, and pillows. For more information, visit www.vytex.com.
About Bryan Stone, MD
Dr. Bryan Stone combines his medical expertise as a board certified internal medicine and nephrology physician with a keen understanding of technology and an aptitude for invention to develop market-changing technologies. Dr. Stone is Desert Regional Medical Center’s Chief of Medicine, Medical Director of Davita Cathedral City Dialysis Clinic, as well as Medical Application Specialist for Fluid Energy Conversion, a green energy division of Vystar with patented disruptive technologies.
Contacts:
Media: Julie Shepherd, Accentuate PR, 847 275 3643, Julie@accentuatepr.com
Investors: Lee Howley, lhowley@vytex.com 508-791-9114
Distributor Opportunities: Steve Rotman, CEO, lhowley@vytex.com 508-791-9114
Forward-looking Statements: Investors are cautioned that certain statements contained in this document as well as some statements in periodic press releases and some oral statements of VYST officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future VYST actions, product development and delivery, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions made and expectations reflected in the forward-looking statements are reasonable, there is no assurance that the underlying assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and VYST has no specific intention to update these statements.
Attachment